Plamotamab
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo[1][2].
Product Specifications
CAS Number
2138442-31-4
Product Name Alternative
XmAb-13676
UNSPSC
12352203
Target
CD20; CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/plamotamab.html
Purity
99.12
Solubility
10 mM in DMSO
Smiles
[plamotamab]
Molecular Weight
(124.88 kDa)
References & Citations
[1]Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63 (3) :738-742. |[2]Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
